CBD2: A functional biomarker database for colorectal cancer
Xueli Zhang,
Min Li,
Siting Ye,
Ke Shen,
Haining Yuan,
Shoaib Bakhtyar,
Qiliang Peng,
Yongsheng Liu,
Yingying Wang,
Manshi Li,
Chi Zhang,
Yixin Wang,
Xiaohe Bai,
Shunming Liu,
Ke Zhao,
Bairong Shen,
Dirk Repsilber,
Guang Hu,
Hong Zhang,
Xiao‐Feng Sun
Affiliations
Xueli Zhang
Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China
Min Li
Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China
Siting Ye
Department of Ultrasound The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China
Ke Shen
Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease‐related Molecular Network, West China Hospital Sichuan University Chengdu China
Haining Yuan
School of Laboratory Medicine and Bioengineering Hangzhou Medical College Hangzhou China
Shoaib Bakhtyar
School of Medicine, Institute of Medical Sciences Örebro University Örebro Sweden
Qiliang Peng
Department of Radiotherapy and Oncology The Second Affiliated Hospital of Soochow University Suzhou China
Yongsheng Liu
Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden
Yingying Wang
Key Laboratory of Public Health Safety, School of Public Health Fudan University Shanghai China
Manshi Li
Key Laboratory of Public Health Safety, School of Public Health Fudan University Shanghai China
Chi Zhang
Department of Otolaryngology Guangzhou Women and Children's Medical Centre Guangzhou China
Yixin Wang
MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Key Laboratory of Pathogen Bioscience and Anti‐infective Medicine, Department of Bioinformatics, Center for Systems Biology, School of Biology and Basic Medical Sciences Suzhou Medical College of Soochow University Suzhou China
Xiaohe Bai
Department of Mathematics University of California San Diego California USA
Shunming Liu
Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Eye Institute Southern Medical University Guangzhou China
Ke Zhao
Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China
Bairong Shen
Institutes for Systems Genetics, Frontiers Science Center for Disease‐Related Molecular Network, West China Hospital Sichuan University Chengdu China
Dirk Repsilber
School of Medicine, Institute of Medical Sciences Örebro University Örebro Sweden
Guang Hu
MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Key Laboratory of Pathogen Bioscience and Anti‐infective Medicine, Department of Bioinformatics, Center for Systems Biology, School of Biology and Basic Medical Sciences Suzhou Medical College of Soochow University Suzhou China
Hong Zhang
School of Medicine, Institute of Medical Sciences Örebro University Örebro Sweden
Xiao‐Feng Sun
Department of Oncology and Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden
Abstract The rapidly evolving landscape of biomarkers for colorectal cancer (CRC) necessitates an integrative, updated repository. In response, we constructed the Colorectal Cancer Biomarker Database (CBD), which collected and displayed the curated biomedicine information for 870 CRC biomarkers in the previous study. Building on CBD, we have now developed CBD2, which includes information on 1569 newly reported biomarkers derived from different biological sources (DNA, RNA, protein, and others) and clinical applications (diagnosis, treatment, and prognosis). CBD2 also incorporates information on nonbiomarkers that have been identified as unsuitable for use as biomarkers in CRC. A key new feature of CBD2 is its network analysis function, by which users can investigate the visible and topological network between biomarkers and identify their relevant pathways. CBD2 also allows users to query a series of chemicals, drug combinations, or multiple targets, to enable multidrug, multitarget, multipathway analyses, toward facilitating the design of polypharmacological treatments for CRC. CBD2 is freely available at http://www.eyeseeworld.com/cbd.
